Transdermal Biotechnology, Inc.

Other

N.v. Perricone LLC

Perriquest Defense Research Enterprises, LLC

Perricone Hydrogen Water Company, LLC

Union Bank of California, N.a.

Perriguest Defense Research Enterprises, LLC

Perricone, Nicholas V.

Nicholas V Perricone

Kristin A Rauschenbach

Chim Potini

Yousry Abdelrehim Sayed

Matthew Partlow

Kurt Rauschenbach

Charles H Cox

Gary E Betts

Harold V Roussell

Jennifer D Traylor Kruschwitz

The present disclosure generally relates to compositions comprising dihexa and methods for making or using said compositions. In some aspects, the compositions disclosed herein may comprise one or more additional active ingredients, including lipoic acid, spadin peptide, and/or phenyl-N-tert-butylnitrone. Compositions such as these may be used in certain embodiments, for example, to enhances a subject's hearing or to treat a hearing disorder, etc. In some embodiments, the compositions are topical compositions configured to treat hearing loss via administration, e.g., to the skin behind the outer ear or directly to the eardrum of a subject, etc. In some cases, the compositions disclosed herein may comprise one or more excipients to aid in transdermal delivery. For instance, in certain embodiments, the compositions comprise lecithin and/or other components that may facilitate delivery through the skin. Other aspects are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Systems and methods for treatment of hearing using dihexa

The present disclosure generally relates to systems and methods for delivering humanin and/or other peptides to a subject. In some cases, these may be used for treating or preventing aging skin, or for other diseases. Non-limiting examples of other peptides include mitochondrial-derived peptides such as HNG or MOTS-c. In addition, certain embodiments are generally directed to treatments that can be delivered using topical compositions applied to the skin. For example, in some cases, the composition includes lecithin and/or other components that may facilitate delivery through the skin. Further, certain embodiments may include active ingredients such as tributyrin or 2,6-dimethyl-L-tyrosine, which may interact with humanin or other peptides. Compositions such as these may be used in certain embodiments, for example, to reduce inflammation within the skin, or as an anti-aging treatment, etc. Other aspects are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Systems and methods for delivery of humanin or other peptides

A plasma engine includes a plasma source having a gas input for receiving a first molecular gas species and that generates ions at an output from the received first molecular gas species. An ion extractor positioned proximate to the output of the plasma source extracts ions from the plasma source with an electric field. A housing includes a region that receives ions extracted from the ion extractor, wherein at least some of the extracted ions react with a second molecular gas species present in the housing to generate thrust.

Plasma engine using ion extraction

A laser protection eyewear lens includes a lens substrate comprising an embedded wavelength filter having a first filter function, and a multi-layer dielectric filter applied to at least one of an inside and an outside surface of the lens substrate that comprises a second filter function having at least one center wavelength and bandwidth. The first filter function of the embedded wavelength filter and the second filter function of the multilayer dielectric filter produce a combined filter function that attenuates light reflecting off the multi-layer dielectric filter.

Laser protection eyewear lenses

A plasma engine includes a plasma source that generates ions from molecular gas species received at a gas input where at least some of the ions generated are atomic species ions. An ion extractor is configured to extract ions from the plasma source with an electric field. A housing comprising a recombination region receives ions extracted from the ion extractor. At least some of the atomic species ions recombine into molecular species in the housing, thereby releasing energy for thrust.

Plasma engine using reactive species

The present invention generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present invention comprises a composition comprising pyruvic acid and/or a pyruvate salt. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Systems and methods for treating vitiligo

Embodiments described herein generally relate to medicinal compositions (e.g., compositions comprising an active pharmaceutical agent) such as those comprising liquid hydrogen and/or hydrogen gas. In certain embodiments, the composition comprises hydrogen and/or noble gas(es) in a medicinal composition, for example, within the aqueous phase (e.g., dissolved). For example, in some cases, the medicinal composition may comprise an active pharmaceutical ingredient and hydrogen (H) and/or noble gas(es). The noble gas may be, for example, xenon, argon, or the like. In some embodiments, the hydrogen and/or the noble gas(es) may infuse with the composition (e.g., such that at least a portion of the hydrogen gas and/or noble gas(es) is dissolved within the composition). Such compositions comprising hydrogen gas and/or noble gas(es) may be useful, for example, for the treatment of animal and human diseases, for improvement in athletic performance, for the enhancement of the overall health of a subject, or the like. Such compositions and/or liquids described herein may be administered (e.g., orally, intravenously, inhaled) to/by a subject.

Medication enhancement using hydrogen

Embodiments described herein generally relate to liquids, such as aqueous solutions, that contain hydrogen gas and palmitoylethanolamide. In certain cases, the liquids may also include active pharmaceutical agents (e.g., cannabinoids), noble gases, and/or other additives. Such liquids may be useful, for example, for increasing a subject's physical energy levels, for improvement in athletic performance, for the enhancement of the overall health of a subject, or the like. Some embodiments relate to liquids disposed within a container (e.g., a sealed container), such that the liquid comprises hydrogen gas and palmitoylethanolamide dissolved or otherwise contained (e.g., suspended and/or infused) in the liquid. The liquids (e.g., aqueous solutions) described herein may be orally administered to a subject (e.g., drunk by a subject). In certain embodiments, the hydrogen gas and/or palmitoylethanolamide may be present in the liquid at a particular concentration (e.g., a physiologically relevant concentration). Advantageously, the compositions, articles, and methods described herein provide liquids containing hydrogen gas and palmitoylethanolamide that are shelf-stable. For example, the liquid composition may maintain a relatively stable concentration of hydrogen gas and/or palmitoylethanolamide for relatively long periods of time (e.g., at least 7 days).

Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof

The present invention generally relates to arrangements for capacitors, for example, for energy storage and other applications. Certain aspects are generally directed to a plurality of capacitors, packed into various 2- and 3-dimensional arrays. The capacitors may have any suitable shape, including spherical and/or cylindrical. The capacitors may be packed into a variety of efficient arrangements, for example, face-centered cubic arrangements, hexagonal close packed arrangements, Barlow packing arrangements, or the like. In some cases, such capacitors may be packed with packing fractions of at least 55%, 60%, or more. Other embodiments of the present invention are generally directed to methods of making or using such capacitor arrangements, kits involving such capacitor arrangements, or the like.

Capacitor arrangements

The present invention generally relates to systems and methods for the transdermal delivery of the heptapeptide ZW1. In some aspects, ZW1 may be contained with a composition comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, liquid crystals, or other configurations. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid 'stick,' etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Growing community of inventors

Madison, CT, United States of America

Nicholas V Perricone